Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04093323 · ClinicalTrials.gov registry record · Phase 2
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
A Phase 2 study, sponsored by Roswell Park Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04093323 is a Phase 2 study that was terminated before completion, run by Roswell Park Cancer Institute. The registered enrollment target is 1 participants.
The verdict
NCT04093323, a Phase 2 study, was terminated before completion, sponsored by Roswell Park Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase II trial studies how well polarized dendritic cell (aDC1) based therapy, interferon alpha-2, rintatolimod, and celecoxib work together in treating patients with HLA-A2 positive (+) melanoma that has not responded to previous treatment (refractory). The aDC1 cell-based treatment contains white blood cells (dendritic cells or DCs) that stimulates the immune system. Interferon alpha-2 can improve the body's natural response to infections and other diseases. It can also interfere with the division of cancer cells and slow tumor growth. Rintalolimid may stimulate the immune system. Celecoxib is a drug that reduces pain. This study is being done to find out if the combination of the study cell-based treatment (aDC1 dendritic cells) and interferon alpha-2, rintatolimod, and celecoxib can prevent the growth and/or progression of melanoma.
Interventions
- DRUG Celecoxib
- BIOLOGICAL Recombinant Interferon Alfa-2b
- BIOLOGICAL Alpha-type-1 Polarized Dendritic Cells
- DRUG PD-1 Ligand Inhibitor
- DRUG PD1 Inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-11-13 |
| Est. Completion | 2025-06-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04093323
The ClinicalTrials.gov registry entry for NCT04093323 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Celecoxib is the first listed.
NCT04093323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04093323 about?
NCT04093323 is a clinical study titled "Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma". This phase II trial studies how well polarized dendritic cell (aDC1) based therapy, interferon alpha-2, rintatolimod, and celecoxib work together in treating patients with HLA-A2 positive (+) melanoma that has not responded to previous treatment (refractory). The aDC1 cell-based treatment contains w...
What is the current status of trial NCT04093323?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2024-11-13. Estimated completion is 2025-06-19.
What interventions are being tested in trial NCT04093323?
The interventions under investigation include: Celecoxib (DRUG), Recombinant Interferon Alfa-2b (BIOLOGICAL), Alpha-type-1 Polarized Dendritic Cells (BIOLOGICAL), PD-1 Ligand Inhibitor (DRUG), PD1 Inhibitor (DRUG).
Who is sponsoring clinical trial NCT04093323?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.